Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer
NCT07419880
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
46
Enrollment
OTHER
Sponsor class
Conditions
Triple -Negative Breast Cancer
Interventions
DRUG:
Cromolyn, TQB2102, and Panpulimab
Sponsor
Fudan University